These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7206588)

  • 41. Reversed-phase liquid chromatography of adriamycin and daunorubicin and their hydroxyl metabolites adriamycinol and daunorubicinol.
    Eksborg S
    J Chromatogr; 1978 Feb; 149():225-32. PubMed ID: 649731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and metabolism of adriamycin in man.
    Benjamin RS; Riggs CE; Bachur NR
    Clin Pharmacol Ther; 1973; 14(4):592-600. PubMed ID: 4723268
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
    Miller AA; Schmidt CG
    Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and disposition of (2''R)-4'-O-tetrahydropyranyladriamycin in dogs.
    Iguchi H; Tone H; Kiyosaki T; Ishikura T; Takeuchi T; Umezawa H
    Jpn J Antibiot; 1986 Feb; 39(2):638-52. PubMed ID: 3712763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.
    Cummings J; Kerr DJ; Kaye SB
    Cancer Chemother Pharmacol; 1987; 20(3):263-4. PubMed ID: 3677300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
    Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
    Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disposition and metabolism of adriamycin in the rat.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 21(4):244-55. PubMed ID: 7422708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
    Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of hyperthermia on the in vitro metabolism of doxorubicin.
    Dodion P; Riggs CE; Akman SR; Bachur NR
    Cancer Treat Rep; 1986 May; 70(5):625-9. PubMed ID: 3708610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
    Israel M; Wilkinson PM; Pegg WJ; Frei E
    Cancer Res; 1978 Feb; 38(2):365-70. PubMed ID: 620407
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of adriamycin and adriamycinol in micro volumes of rat plasma.
    Bots AM; Van Oort WJ; Noordhoek J; Van Dijk A; Klein SW; Van Hoesel QG
    J Chromatogr; 1983 Feb; 272(2):421-7. PubMed ID: 6833441
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
    Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
    Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapeutic efficiency of adriamycin in mice, bearing transplanted or autochthonous solid tumors. Drug and fluorescent metabolites plasmatic levels (author's transl)].
    Denechaud M; Laval M; Robert J; Ducassou D
    Bull Cancer; 1981; 68(4):313-20. PubMed ID: 6797492
    [No Abstract]   [Full Text] [Related]  

  • 54. Antitumor activity and metabolism of a new anthracycline-containing fluorine (ME2303) in Lewis lung carcinoma-bearing mice.
    Iigo M; Hoshi A; Kadosawa H; Fujigaki M
    Jpn J Cancer Res; 1991 Nov; 82(11):1317-21. PubMed ID: 1752788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary phase I study of 4'-epi-adriamycin.
    Bonfante V; Bonadonna G; Villani F; Di Fronzo G; Martini A; Casazza AM
    Cancer Treat Rep; 1979 May; 63(5):915-8. PubMed ID: 455333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adriamycin and daunorubicin disposition in the rabbit.
    Bachur NR; Hildebrand RC; Jaenke RS
    J Pharmacol Exp Ther; 1974 Nov; 191(2):331-40. PubMed ID: 4417723
    [No Abstract]   [Full Text] [Related]  

  • 57. Quantitative thin-layer chromatographic measurement of n-trifluoroacetyladriamycin-14-valerate (AD 32) and trifluoroacetyladriamycin (AD 41) in blood and tissues.
    Barbieri B; Abbruzzi R; Benigni A; Rizzardini M; Donelli MG; Garattini S; Salmona M
    J Chromatogr; 1979 Jun; 163(2):195-200. PubMed ID: 541371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model.
    Behnia K; Boroujerdi M
    Cancer Chemother Pharmacol; 1998; 41(5):370-6. PubMed ID: 9523732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice.
    Shen LF; Zhang YD; Shen HJ; Zeng S; Wang X; Wang C; Le Y; Shen H
    Chin Med J (Engl); 2006 Aug; 119(15):1287-93. PubMed ID: 16919188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion.
    Speth PA; Linssen PC; Holdrinet RS; Haanen C
    Clin Pharmacol Ther; 1987 Jun; 41(6):661-5. PubMed ID: 3581649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.